Nichi-Iko Quits Herceptin Biosimilar, Focus Now on Avastin Follow-On

Japanese generic major Nichi-Iko Pharmaceutical said on January 17 that it will discontinue its Herceptin (trastuzumab) biosimilar program, which has been in PI in the US, as it now wants to sharpen its focus on its Avastin (bevacizumab) follow-on. Nichi-Iko...read more